Food poisoning due to Salmonella contamination of undercooked meat, usually chicken and eggs, is a major concern for human health and agribusiness. Infection with Salmonella causes Salmonellosis characterized by diarrhea, fever, and abdominal cramps 12-72 hours after ingestion. According to the U.S. Centers for Disease Control (CDC) the annual incidence of Salmonellosis in the US is approximately 42,000 cases; however, many infections are not reported and the actual rate is thought to be ~1.2 million cases. With this number of cases and the overwhelming number of serovars, classification amongst subspecies can be cumbersome. In a recent comparison study, LGC Clinical Diagnostic's KPL BacTrace® Anti-Salmonella CSA-Plus Antibody showed advantageous reactivity to most Salmonella O-antigens and high specificity to Salmonella with low cross-reactivity to non-Salmonella bacteria due to the propriety affinity purification methods. To learn more, read this application note by clicking the link: https://hubs.ly/Q02NCrBs0 #antigens #ELISA #foodcontamination
About us
LGC Clinical Diagnostics develops and manufactures a comprehensive portfolio of catalog and custom-developed diagnostic quality solutions, biological and reagent component materials for the extended life sciences industry. Our scientific expertise, together with our custom product development capabilities, further accelerates bringing your innovations to life. Together, we are changing the future of diagnostics. LGC Clinical Diagnostics has over 35 years of experience as a leading and trusted global manufacturer of Quality Management Tools (QMT) and reagent components. We partner with In Vitro Diagnostics (IVD) and biopharmaceutical developers, clinical research organizations (CROs) and academic institutions in commercialization activities across the entire diagnostic pipeline - from concept and early-stage research, through expedited product development and onwards into routine clinical use. Laboratories and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics, and clinical genomics rely on LGC’s products to achieve accurate and reliable diagnostic results. Our combined and ever-growing capabilities mean we are better positioned to support the needs of the clinical diagnostics industry, from early feasibility and research to commercial & laboratory development test (LDT) assay development, installation, validation and ongoing performance monitoring support. LGC Clinical Diagnostics Quality Management and reagent component manufacturing facilities are FDA-registered, and ISO 13485 and ISO 9001-certified. Our brands include Technopath Clinical Diagnostics, SeraCare, Biochemical Diagnostics, Inc., KOVA International, Maine Standards, and The Native Antigen Company. Together, our brands serve over 7,500 customers in over 120 countries, providing products for more than 20 clinical application areas, including infectious diseases, NIPT, diabetes, cardiac disease and oncology.
- Website
-
https://lgcclinicaldiagnostics.com
External link for LGC Clinical Diagnostics
- Industry
- Biotechnology
- Company size
- 1,001-5,000 employees
- Headquarters
- Milford, Massachusetts
- Type
- Privately Held
- Specialties
- linearity and calibration verification, reference materials, antigens and antibodies, research components, biological materials, Quality Measurement Tools, Informatics, and Quality Controls
Locations
Employees at LGC Clinical Diagnostics
-
Len Lloyd
Director, Corporate Accounts LGC Diagnostics & Genomics
-
Scott Wassel
-
Cliff Schwartz
Medical Device Quality Engineer at LGC Clinical Diagnostics, Inc.
-
Tony Blankenship
Technical Application Specialist @ LGC Clinical Diagnostics | Workload Prioritization, Escalations Management
Updates
-
While attending ADLM 2024, Ken Yoon and Bharathi Anekella spoke to SelectScience about the mission and values driving Biosearch Technologies and LGC Clinical Diagnostics. Learn about our wide range of products and services, the collaborative synergy between the two branches, and the vision for advancing the future of clinical diagnostics and genomics: https://hubs.ly/Q02N45Rj0 #ADLM2024
A partner providing excellence in assay development and diagnostics
selectscience.net
-
Up to 50% of metastatic breast cancer patients harbor ESR1 mutations - critical drivers that can dictate treatment success. Introducing our new Seraseq ctDNA ESR1 Reference Materials - designed to accelerate the validation and clinical implementation of liquid biopsy assays in metastatic breast cancer (MBC). These Reference Materials include 22 clinically relevant mutations in ESR1 and PIK3CA genes at a 1% variant allele frequency (VAF), simulating real-world conditions to challenge and validate assay accuracy in detecting key mutations that guide treatment decisions. Learn more & access the product sheet for a detailed list of mutations and features here: https://hubs.ly/Q02MLm4n0 #BreastCancer #LiquidBiopsy #ctDNA #MBC #ESR1 #PIK3CA #PrecisionMedicine
-
We are happy to announce that while attending the Sonora Quest Laboratories & Laboratory of Sciences of Arizona 2024 Supplier Summit, our team received the Innovation Award for our daily quality control Multichem® products. Due to the use of Multichem, their lab experienced many efficiencies helping them optimize their daily processes and procedures. Learn more about Multichem here: https://hubs.ly/Q02MJ9Hd0
Multichem Third Party Quality Controls Overview
technopathclinicaldiagnostics.com
-
August 2024 Recap: We’ve had an exciting month—here’s what you might’ve missed! -New Blog: Uncovering the Hidden Code of Carrier Screening. -Product Spotlight: Seraseq Carrier Screening DNA Mix—54 key variants, 48 genes. -Cancer Monitoring: Streamline your workflow with our Seraseq Tumor Monitoring Solutions. -Milestone: 150+ Peer-Reviewed Publications across NGS, oncology, and reproductive health. -Upcoming Event: Meet us at ESMO Congress 2024 in Barcelona, Booth 340. Curious to learn more? Explore the full spectrum of our latest research and technological advancements here: https://hubs.ly/Q02LXYfT0 #CarrierScreening #GeneticTesting #NGS #CancerMonitoring #OncologySolutions #TumorMonitoring #PeerReviewed #ClinicalGenomics #ESMO2024 #ReproductiveHealth
, here's what you missed in August!
email.seracare.com
-
We are pleased to share our comprehensive suite of Seraseq® Tumor Monitoring Solutions, meticulously crafted to enhance and streamline your cancer monitoring workflow. Our FFPE TMB, gDNA TMB, MRD, and bTMB products are derived from tumor-matched, patient samples to ensure the accuracy and consistency needed at every stage of solid tumor treatment and recurrence monitoring. We've developed a user-friendly landing page to help you explore these solutions in detail. Click below to see how our reference materials can support your workflow: Optimize Your Cancer Monitoring Workflow with Patient-Derived Reference Materials https://hubs.ly/Q02Lt9pP0 #CancerResearch #Oncology #TumorMonitoring #Genomics #PrecisionMedicine #NGS #CancerDiagnostics #TMB #MRD #LiquidBiopsy #FFPE #GenomicData #ClinicalGenomics
Optimize Your Cancer Monitoring Workflow with Patient-Derived Reference Materials
-
In conjunction with the new product launch of our Seraseq Carrier Screening DNA Mix, our blog "Carrier Screening: Uncovering The Hidden Code" discusses the importance of carrier screening for prospective parents, as one in four individuals is a carrier of a genetic disease. It also highlights how our reference material can help identify hidden genetic risks. We encourage you to take advantage of these valuable resources to enhance your understanding and decision-making in reproductive health! Carrier Screening: Uncovering The Hidden Code https://hubs.ly/Q02KPcSV0 #CarrierScreening #GeneticTesting #ReproductiveHealth
Carrier Screening: Uncovering The Hidden Code
blog.lgcclinicaldiagnostics.com
-
One in four people is a carrier of a genetic disease. Understanding carrier screening is crucial for anyone considering parenthood. Our latest blog highlights how this essential genetic testing can inform your reproductive health decisions. Also, learn about our carrier screening reference material that identifies hidden genetic risks and empowers you to make informed choices. HOT OFF THE PRESS! Read our latest blog. Carrier Screening: Uncovering The Hidden Code https://hubs.ly/Q02JTFwN0 #CarrierScreening #GeneticTesting #ReproductiveHealth #InheritedConditions #GeneticCounseling #FutureGenerations #CysticFibrosis #SickleCellDisease #TaySachs #SpinalMuscularAtrophy #GeneticCarriers #ReproductiveChoices #GeneticRisk #PrecisionHealth
Carrier Screening: Uncovering The Hidden Code
blog.lgcclinicaldiagnostics.com
-
It is the final day of ADLM 2024! The LGC Clinical Diagnostics and LGC Biosearch Technologies Team want to show our appreciation for all the connections we made this week and the relationships we can continue to foster because of this event. Additionally, we are thrilled to share that we have been awarded two Clinical Diagnostics Scientists’ Choice Awards announced by the SelectScience® editorial team: 🏆Clinical Diagnostics Webinar of the Year for "Quality Control in Medical Laboratories for Beginners" 🏆Clinical Diagnostics Campaign of the Year To everyone who stopped by the booth, THANK YOU! #ADLM2024 #UNI5K #strongertogether
-
We're at ADLM! Visit booth #2845 to speak to a member of the LGC Clinical Diagnostics and LGC Biosearch Technologies Team. Also don't forget to stop by our poster presentation in the poster hall today from 1:30 - 2:30 PM CT! Want a digital copy? Request access to the poster here: https://hubs.ly/Q02JpXJr0 #ADLM2024 #scientificposter #strongertogether
ADLM 2024 Scientific Poster Request
digital.lgcclinicaldiagnostics.com